<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621904</url>
  </required_header>
  <id_info>
    <org_study_id>2017-3803</org_study_id>
    <nct_id>NCT03621904</nct_id>
  </id_info>
  <brief_title>PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer</brief_title>
  <acronym>PROMOTE</acronym>
  <official_title>PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holycross Cancer Center Kielce</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Cornwall Hospitals Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent
      endometrial cancer analysing tumor tissue taken before start of hormonal therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is limited consensus about the position of hormonal treatment in advanced and
      metastatic endometrial carcinoma (EC). This is due to lack of good quality data on patient
      selection, and predictive biomarkers. Consequently, consideration of hormonal therapy is
      subjected to personal experience of the treating physician, rather than on refined clinical
      and up-to-date molecular criteria. Hormonal therapy has limited side-effects, and is better
      tolerated than systematic chemotherapy. Since EC patients are often elderly women with
      comorbidities, more effective and less aggressive treatment options are needed, underlining
      the urgency of an explorative study on this topic.

      Endometrial cancer is the most common malignancy of the female genital tract in developed
      countries, with increasing incidence due to obesity and increased life expectancy. Most
      patients are diagnosed at an early stage, and have a favourable prognosis with surgery alone.
      Yet, 20% of the patients present with advanced or metastatic EC and have a poor outcome even
      with systemic treatment. Response rate of chemotherapy in advanced or metastatic EC is
      30-60%, dependent of previous chemotherapy, with a progression free survival (PFS) of 3-14
      months and 40% treatment related morbidity. In comparison, response to hormonal therapy is
      20%-40%, with side effects in less than 5%. The overall PFS is 3 months, yet for those who
      respond the PFS can be up to several years.

      To improve selective use of hormonal therapy in EC by evaluating applied hormonal therapy in
      advanced and metastatic EC and correlate response to molecular tumour analysis and translate
      this knowledge after validation into clinical practice
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Relate clinical response to tumor factors</measure>
    <time_frame>4 years</time_frame>
    <description>Define clinical response to hormonal treatment in endometrial cancer, in relation to:
immunohistochemical expression of estrogen, progesterone and androgen receptors
estrogen and progesterone receptor signaling pathway activity
intracellular steroid metabolism</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Endometrial Cancer Stage III</condition>
  <condition>Endometrial Cancer Stage IV</condition>
  <condition>Endometrial Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>EC patients with HT</arm_group_label>
    <description>Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormonal Antineoplastics</intervention_name>
    <description>Hormonal therapy used for treatment in endometrial cancer patients</description>
    <arm_group_label>EC patients with HT</arm_group_label>
    <other_name>Progersterone</other_name>
    <other_name>Tamoxifen</other_name>
    <other_name>Aromatase inhibitors</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor samples originating from before start of hormonal therapy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced stage and recurrent endometrial cancer treated with hormonal
        treatment, available biopsy prior to start of hormonal treatment and available follow-up
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer

          -  All histologic types of endometrial carcinoma

          -  Planned treatment with any type of hormonal therapy

          -  Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent
             therapy between biopsy and start of hormonal therapy.

        Exclusion Criteria:

          -  Adjuvant hormonal therapy started following complete resection of endometrial
             carcinoma

          -  Synchronous use of hormonal therapy for other indications

          -  Endometrial sarcoma or endometrial stroma cell sarcoma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>People with endometrial carcinoma can participate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanny Pijnenborg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camilla Krakstad, MD PhD prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukelund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Romano, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Willem Jan Van Weelden, MD</last_name>
    <phone>+31655722863</phone>
    <email>willemjan.vanweelden@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanny Pijnenborg, MD PhD</last_name>
    <phone>+31243616683</phone>
  </overall_contact_backup>
  <reference>
    <citation>Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S96-104. doi: 10.1016/j.ijgo.2015.06.005.</citation>
    <PMID>26433681</PMID>
  </reference>
  <reference>
    <citation>Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol. 1991 Jun;9(6):1071-88. Review.</citation>
    <PMID>2033421</PMID>
  </reference>
  <reference>
    <citation>Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66.</citation>
    <PMID>15169803</PMID>
  </reference>
  <reference>
    <citation>Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):964-78. Epub 2007 Apr 18. Review.</citation>
    <PMID>17442022</PMID>
  </reference>
  <reference>
    <citation>Ethier JL, Desautels DN, Amir E, MacKay H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol. 2017 Oct;147(1):158-166. doi: 10.1016/j.ygyno.2017.07.002. Epub 2017 Jul 6. Review.</citation>
    <PMID>28689667</PMID>
  </reference>
  <reference>
    <citation>Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016 Jan;26(1):2-30. doi: 10.1097/IGC.0000000000000609.</citation>
    <PMID>26645990</PMID>
  </reference>
  <reference>
    <citation>Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.</citation>
    <PMID>27348297</PMID>
  </reference>
  <reference>
    <citation>Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, Akslen L, Moerman P, Vergote I, Salvesen H, Amant F. Evolution in endometrial cancer: evidence from an immunohistochemical study. Int J Gynecol Cancer. 2011 Feb;21(2):316-22. doi: 10.1097/IGC.0b013e31820575f5.</citation>
    <PMID>21734474</PMID>
  </reference>
  <reference>
    <citation>Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM, Werner HM, Trovik J, Kalland KH, Salvesen HB, Krakstad C. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget. 2016 Aug 2;7(31):49289-49298. doi: 10.18632/oncotarget.10334.</citation>
    <PMID>27384477</PMID>
  </reference>
  <reference>
    <citation>Verhaegh W, van Ooijen H, Inda MA, Hatzis P, Versteeg R, Smid M, Martens J, Foekens J, van de Wiel P, Clevers H, van de Stolpe A. Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Res. 2014 Jun 1;74(11):2936-45. doi: 10.1158/0008-5472.CAN-13-2515. Epub 2014 Apr 2.</citation>
    <PMID>24695361</PMID>
  </reference>
  <reference>
    <citation>Cornel KM, Kruitwagen RF, Delvoux B, Visconti L, Van de Vijver KK, Day JM, Van Gorp T, Hermans RJ, Dunselman GA, Romano A. Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol. J Clin Endocrinol Metab. 2012 Apr;97(4):E591-601. doi: 10.1210/jc.2011-2994. Epub 2012 Feb 22.</citation>
    <PMID>22362820</PMID>
  </reference>
  <reference>
    <citation>Cornel KM, Krakstad C, Delvoux B, Xanthoulea S, Jori B, Bongers MY, Konings GF, Kooreman LF, Kruitwagen RF, Salvesen HB; ENITEC, Romano A. High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. Mol Cell Endocrinol. 2017 Feb 15;442:51-57. doi: 10.1016/j.mce.2016.11.030. Epub 2016 Dec 5.</citation>
    <PMID>27923582</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormonal therapy</keyword>
  <keyword>Endocrine therapy</keyword>
  <keyword>Translational research</keyword>
  <keyword>Tumor factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Antineoplastic Agents, Hormonal</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This is not yet established</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

